However, the evaluation of combination therapies that include IFN-γ can be a valuable road to keep in consideration towards an immune therapy for treatment of COVID-19 that prompts further studies to understand whether the other kinds of IFN use different effectors to restrict this pandemic virus. The gene discussed is IFNG; the disease is COVID-19.